Recruiting Geographic Atrophy Studies in Scottsdale
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the orga...
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)
The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD)....
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the doubl...
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module...
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction canc...
About Geographic Atrophy Clinical Trials in Scottsdale
Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.
There are currently 6 geographic atrophy clinical trials recruiting participants in Scottsdale, ARIZONA. These studies are seeking a combined 3,410 participants. Research is being sponsored by Guerbet, Annexon, Inc., Simcha IL-18, Inc. and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Geographic Atrophy Clinical Trials in Scottsdale — FAQ
Are there geographic atrophy clinical trials in Scottsdale?
Yes, there are 6 geographic atrophy clinical trials currently recruiting in Scottsdale, ARIZONA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Scottsdale?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Scottsdale research site will contact you about next steps.
Are clinical trials in Scottsdale free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Scottsdale studies also compensate for your time and travel.
What geographic atrophy treatments are being tested?
The 6 active trials in Scottsdale are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.
Data updated March 2, 2026 from ClinicalTrials.gov